Pharmacokinetic/pharmaeodynamic factors influencing emergence of resistance to linezolid in an in vitro model

被引:49
作者
Boak, Lauren M. [1 ]
Li, Jian [1 ]
Rayner, Craig R. [1 ]
Nation, Roger L. [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Facil Antiinfect Drug Dev & Innovat, Parkville, Vic 3052, Australia
关键词
D O I
10.1128/AAC.01194-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Emerging resistance threatens the usefulness of linezolid for the treatment of severe infections caused by multidrug-resistant gram-positive bacteria. Optimal pharmacokinetic (PK)/pharmacodynamic (PD) indices have been described for the antimicrobial efficacy of linezolid (area under the concentration-time curve over 24 h at steady state divided by the MIC, > 100; the cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state PK conditions, > 85). The aim of this study was to investigate the influence of these PK/PD indices on the development of resistance to linezolid by using an in vitro PK/PD model. Four dosage regimens were simulated over 72 h (two intermittent bolus regimens of 600 mg every 12 h [q12h] and 120 mg q12h and two continuous-infusion regimens of 120 mg/24 h and 30 mg/24 h) against four reference strains: methicillin-resistant Staphylococcus aureus (MRSA), heteroresistant vancomycin-intermediate S. aureus (hVISA), vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant Enterococcus-faecium (VRE). Linezolid concentrations were measured by high-performance liquid chromatography. Changes in susceptibility were characterized by pre- and posttreatment MIC measurements and population analysis profiles (PAPs). The linezolid concentrations that were achieved closely matched those that were targeted. The simulation with 600 mg q12h provided a > 3-log(10) reduction in the number of CFU/ml for all four strains, as did the 120-mg-q12h regimen for hVISA and VISA and the 30-mg/24-h continuous infusion for VRE and VISA. After 72 h of exposure to the 120-mg/24-h continuous-infusion simulation, the area under the PAP curve for all strains increased substantially (40 to 178%); increases in the MICs for the MRSA and hVISA strains were observed. The results demonstrate that PK/PD considerations are important in optimizing both antibacterial activity and the development of resistance to linezolid. The potential for resistance development appears to be higher when a constant concentration is maintained in the vicinity of the MIC of the bacteria.
引用
收藏
页码:1287 / 1292
页数:6
相关论文
共 33 条
[1]   In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model [J].
Allen, GP ;
Cha, R ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2606-2612
[2]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[3]  
[Anonymous], 2003, M7A6 CLIN LAB STAND
[4]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[5]  
Cammarata SK, 2000, CLIN MICROBIOL INFEC, V6, P136
[6]   Linezolid, levofloxacin, and vancomycin against vancomycin-tolerant and fluoroquinolone-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model [J].
Cha, R ;
Akins, RL ;
Rybak, MJ .
PHARMACOTHERAPY, 2003, 23 (12) :1531-1537
[7]   Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations [J].
Cha, R ;
Brown, WJ ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3960-3963
[8]   Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant Streptococcus pneumoniae strain in an in vitro pharmacodynamic model [J].
Cha, R ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1984-1987
[9]   Linezolid [J].
Clemett, D ;
Markham, A .
DRUGS, 2000, 59 (04) :815-827
[10]   Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus [J].
Dailey, CF ;
Dileto-Fang, CL ;
Buchanan, LV ;
Oramas-Shirey, MP ;
Batts, DH ;
Ford, CW ;
Gibson, JK .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2304-2308